Passage Bio (PASG) - P/E Multiple
This price chart on GURU.Markets illustrates the performance of Passage Bio, Inc. (PASG), where the metric value stands at -0.30. The business relies on exclusive treatments for rare pediatric brain pathologies, which ensures stable revenue due to its orphan drug status. However, a mono-platform strategy creates binary risks associated with the safety of delivery methods. Development is conducted in US laboratories using innovative viral vectors.
Comprehensive metric breakdowns and analytics for Passage Bio Inc. (PASG)
- stock price and consensus target price:
- market capitalization indicators:
- company book value details:
- company liabilities and liquidity data:
Total Debt to Capital Passage Bio, Inc.|PASG - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Passage Bio Corp|PASG - Company Aggregate Debts|Debts to Book Value Passage Bio, Inc.|PASG - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Passage Bio|Quick Liquidity passagebio.com
- earnings and market multiples details:
PASG - Net Profit|Company Profit Forecast Passage Bio, Inc.|PASG - Price to Earnings Ratio|Projected Price to Earnings Ratio Passage Bio Corp|PASG - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Passage Bio, Inc.|PASG - Operating profit EBITDA|Net earnings per share for the last four quarters Passage Bio|PASG - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months passagebio.com|PASG - Earnings growth in current year|Expected earnings per share growth for next year Passage Bio, Inc.
Summary company analysis:PASG (passagebio.com)
The P/E ratio determines the investment payback period by comparing a stock's market value with the business's net profit to assess whether an asset is overbought or undervalued. By analyzing P/E valuation trends, an investor determines the risk of capital drawdown, which is critical for Passage Bio, Inc. (PASG) during the organic development of key CNS drugs following a portfolio reduction and the abandonment of M&A deals.
Competing companies
biogen.com - Market Cap to Net Income|P/E Multiple NBIX|P/E Multiple Regencell Bioscience Ltd (RGC)|Price to Earnings Ratio Axsome Therapeutics Inc AXSM|Business Payback Period ACADIA Corp (ACAD)|XENE - Price to Earnings Ratio|Business Payback Period vikingtherapeutics.com VKTX|SUPN: P/E Multiple|Catalyst Pharma (CPRX) - P/E Multiple|DNLI (Denali Therapeutics Inc) - P/E Multiple|HRMY - Market Cap to Net Income Ratio|P/E Multiple BHVN|AMLX - Market Cap to Earnings|Trevi Therapeutics, Inc. - Price to Earnings Ratio|Company Value to Net Income PRAX|Anavex Corp - P/E Multiple|CBLL: Price to Earnings Ratio|PRTA: P/E Multiple|ALEC - Business Payback Period|Price to Earnings Ratio Annexon|Market Cap to Earnings Omeros Corp. OMER|Price to Earnings Ratio NGNE (Neurogene Corp)|ACIU (AC Immune Inc) - Company Value to Net Income|P/E Multiple VYGR (Voyager Therapeutics)|Business Payback Period neumoratx.com (NMRA)|SCLX - Price to Earnings Ratio|TVGN (Tevogen Bio Holdings Inc.) - Price to Earnings Multiple|ACOG: P/E Multiple|Price to Earnings Ratio Cognition Therapeutics Inc.|Price to Earnings Ratio IKT|cassavasciences.com (SAVA) - Business Payback Period|Price to Earnings Ratio Assertio Holdings, Inc. (ASRT)|COYA: Market Cap to Net Income|P/E Multiple VTGN (Vistagen)|P/E Multiple Ovid Therapeutics Inc OVID|ABOS - Price to Earnings Ratio|Business Payback Period cervomed.com CRVO|ATHE: P/E Multiple|Market Cap to Net Income Ratio Clene CLNN|Price to Earnings Ratio PepGen Inc|Price to Earnings Multiple JUNS (Jupiter Neurosciences, Inc.)|P/E Multiple RLMD|ANVS - Market Cap to Earnings|Grace Therapeutics - Price to Earnings Ratio|P/E Multiple Firefly Neuroscience, Inc. AIFF|KLTO - Price to Earnings Ratio|Company Value to Net Income NRSN (NeuroSense Therapeutics)|Reviva Pharmaceuticals (RVPH) - Price to Earnings Ratio|Market Cap to Earnings MetaVia (MTVA)|Price to Earnings Ratio NeurAxis|Helius Medical Technologies Inc. - Market Cap to Net Income|P/E Multiple NEUP|P/E Multiple Minerva (NERV)|Price to Earnings Ratio Athira Pharma, Inc. ATHA|Business Payback Period addextherapeutics.com (ADXN)|ALZN - Price to Earnings Ratio|Business Payback Period Cyclerion Therapeutics CYCN|PTIX: P/E Multiple|Pasithea Therapeutics Corp. (KTTA) - P/E Multiple|CRGT (Cortigent Inc) - P/E Multiple|ATXI - Market Cap to Net Income Ratio|P/E Multiple BCLI|CARA - Market Cap to Earnings|Chromocell Therapeutics Corporation - Price to Earnings Ratio|Company Value to Net Income ELYM|Intra-Cellular - P/E Multiple|LBPH: Price to Earnings Ratio|MRNS: P/E Multiple|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo|Market Cap to Earnings Sage Therapeutics Inc SAGE|Price to Earnings Ratio SNPX (Synaptogenix, Inc.)|TRVN (trevena.com) - Company Value to Net Income|P/E Multiple VIGL (Vigil Neuroscience, Inc.)|Business Payback Period anewmeds.com (WENA)|CERE - Price to Earnings Ratio
